HUP0000138A2 - Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények - Google Patents

Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények

Info

Publication number
HUP0000138A2
HUP0000138A2 HU0000138A HUP0000138A HUP0000138A2 HU P0000138 A2 HUP0000138 A2 HU P0000138A2 HU 0000138 A HU0000138 A HU 0000138A HU P0000138 A HUP0000138 A HU P0000138A HU P0000138 A2 HUP0000138 A2 HU P0000138A2
Authority
HU
Hungary
Prior art keywords
controlled
pharmaceutical compositions
compositions containing
release pharmaceutical
containing opioid
Prior art date
Application number
HU0000138A
Other languages
English (en)
Inventor
Johannes Bartholomäus
Jürgen Betzing
Original Assignee
GRÜNENTHAL GmbH,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRÜNENTHAL GmbH, filed Critical GRÜNENTHAL GmbH,
Publication of HU0000138D0 publication Critical patent/HU0000138D0/hu
Publication of HUP0000138A2 publication Critical patent/HUP0000138A2/hu
Publication of HUP0000138A3 publication Critical patent/HUP0000138A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A találmány tárgya valamely opioid analgetikum szabályozott leadásátbiztosító, orálisan adagolandó készítmény, amely 10 mm és 3 mmközötti, előnyösen 50 mm és 1 mm közötti részecskenagyságú kristályokalakjában valamely opioid analgetikumot és legalább egyretardálóbevonatot tartalmaz. Ó
HU0000138A 1999-01-18 2000-01-17 Controlled-release pharmaceutical compositions containing opioid analgetics HUP0000138A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901687A DE19901687B4 (de) 1999-01-18 1999-01-18 Opioide Analgetika mit kontrollierter Wirkstofffreisetzung

Publications (3)

Publication Number Publication Date
HU0000138D0 HU0000138D0 (en) 2000-03-28
HUP0000138A2 true HUP0000138A2 (hu) 2001-02-28
HUP0000138A3 HUP0000138A3 (en) 2001-03-28

Family

ID=7894566

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000138A HUP0000138A3 (en) 1999-01-18 2000-01-17 Controlled-release pharmaceutical compositions containing opioid analgetics

Country Status (24)

Country Link
US (1) US6685964B1 (hu)
EP (1) EP1020185B1 (hu)
JP (1) JP2000212072A (hu)
KR (1) KR20000071247A (hu)
CN (1) CN1244327C (hu)
AR (1) AR022254A1 (hu)
AT (1) ATE257012T1 (hu)
AU (1) AU771064B2 (hu)
CA (1) CA2295471A1 (hu)
CO (1) CO5251462A1 (hu)
DE (2) DE19901687B4 (hu)
DK (1) DK1020185T3 (hu)
ES (1) ES2213971T3 (hu)
HK (1) HK1029749A1 (hu)
HU (1) HUP0000138A3 (hu)
IL (1) IL134076A (hu)
NZ (1) NZ502261A (hu)
PE (1) PE20001395A1 (hu)
PL (1) PL337867A1 (hu)
PT (1) PT1020185E (hu)
RU (1) RU2239417C2 (hu)
SI (1) SI1020185T1 (hu)
SK (1) SK285129B6 (hu)
ZA (1) ZA200000173B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149352A0 (en) 1999-10-29 2002-11-10 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ES2228789T3 (es) * 2000-09-22 2005-04-16 Smb Technology Composicion oral de tramadol en forma de granulados para tomar una vez por dia.
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
EP1389092B1 (en) * 2001-05-11 2006-11-15 Endo Pharmaceuticals Inc. Abuse-resistant opioid dosage form
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1476155A4 (en) * 2002-01-23 2009-10-28 Univ California METHODS AND COMPOSITIONS FOR REDUCING THE DEVELOPMENT OF DRUG TOLERANCE AND / OR PHYSICAL DEPENDENCE
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US20040156844A1 (en) * 2002-05-22 2004-08-12 Curtis Wright Tamper resistant oral dosage form
WO2004026308A1 (fr) * 2002-09-21 2004-04-01 Shuyi Zhang Compose d'acetamidophenol et de tramadol a liberation prolongee
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
ES2360102T3 (es) 2003-03-26 2011-05-31 Egalet A/S Sistema para la liberación controlada de morfina.
CN100336501C (zh) * 2003-08-06 2007-09-12 健乔信元医药生技股份有限公司 醋炎痛缓释性圆粒组成物及制备方法
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
EP1754471A1 (de) * 2005-08-18 2007-02-21 ORAMON-Arzneimittel GmbH & Co. KG Verwendung einer quellbaren Zwischenschicht zur Steuerung des Freisetzungsprofils einer festen Arzneimittelformulierung zur peroralen Anwendung und diese enthaltende Arzneimittelformulierung
ES2620293T3 (es) 2005-09-09 2017-06-28 Paladin Labs Inc. Composición de liberación sostenida de fármacos
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US9265732B2 (en) * 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
WO2007103113A2 (en) * 2006-03-06 2007-09-13 Pozen Inc. Dosage forms for administering combinations of drugs
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
GB0625646D0 (en) * 2006-12-21 2007-01-31 Jagotec Ag Improvements in or relating to organic compounds
NZ580972A (en) 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
GB0714790D0 (en) * 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
US9220698B2 (en) 2008-09-09 2015-12-29 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
WO2010099508A1 (en) * 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
EP2445344A4 (en) * 2009-06-25 2013-01-23 Pozen Inc METHOD FOR THE TREATMENT OF A PATIENT REQUIRED BY ASPIRIN THERAPY
EP2568977A1 (en) 2010-05-11 2013-03-20 Cima Labs Inc. Alcohol-resistant metoprolol-containing extended- release oral dosage forms
UA115139C2 (uk) 2011-12-28 2017-09-25 Поузен Інк. Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CN106176683B (zh) * 2016-08-31 2019-04-16 贵州益康制药有限公司 一种盐酸曲马多缓释胶囊及其制备方法和用途
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
IE59287B1 (en) * 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
US5095151A (en) * 1985-05-21 1992-03-10 American Home Products Corporation Preparation of propranolol hydrochloride macrocrystals
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
EP2036558A3 (en) * 1993-10-07 2010-04-28 Euro-Celtique S.A. Orally administrable opioid formulations having extended duration of effect
EP0654263B1 (en) * 1993-11-23 2002-01-23 Euro-Celtique S.A. Method for preparing a sustained release composition
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
DE19901683B4 (de) * 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung

Also Published As

Publication number Publication date
KR20000071247A (ko) 2000-11-25
AU1011300A (en) 2000-07-20
DE19901687A1 (de) 2000-07-20
JP2000212072A (ja) 2000-08-02
SK642000A3 (en) 2000-08-14
IL134076A (en) 2005-05-17
EP1020185A2 (de) 2000-07-19
DK1020185T3 (da) 2004-02-16
AR022254A1 (es) 2002-09-04
EP1020185B1 (de) 2004-01-02
NZ502261A (en) 2001-11-30
ATE257012T1 (de) 2004-01-15
CO5251462A1 (es) 2003-02-28
SK285129B6 (sk) 2006-07-07
ZA200000173B (en) 2000-08-07
DE19901687B4 (de) 2006-06-01
SI1020185T1 (en) 2004-04-30
CA2295471A1 (en) 2000-07-18
HU0000138D0 (en) 2000-03-28
CN1244327C (zh) 2006-03-08
DE59908195D1 (de) 2004-02-05
PT1020185E (pt) 2004-05-31
US6685964B1 (en) 2004-02-03
PE20001395A1 (es) 2000-12-23
HUP0000138A3 (en) 2001-03-28
PL337867A1 (en) 2000-07-31
HK1029749A1 (en) 2001-04-12
EP1020185A3 (de) 2000-09-27
AU771064B2 (en) 2004-03-11
IL134076A0 (en) 2001-04-30
RU2239417C2 (ru) 2004-11-10
CN1270029A (zh) 2000-10-18
ES2213971T3 (es) 2004-09-01

Similar Documents

Publication Publication Date Title
HUP0000138A2 (hu) Szabályozott hatóanyag-leadású opioid analgetikumokat tartalmazó gyógyászati készítmények
CA2339991A1 (en) Microemulsions as solid dosage forms for oral administration
HUP0401191A2 (hu) Opioid agonistát, valamint leadható és álcázott antagonistát tartalmazó készítmények
MXPA04003132A (es) Formas orales de administracion de propiverina o sus sales farmaceuticas aceptables con liberacion prolongada.
CA2427815A1 (en) Controlled release hydrocodone formulations
WO2003013433A3 (en) Sequestered antagonist formulations
HUP0002316A2 (hu) Gyorsan olvadó orális adagolási formák
HUP0203176A2 (hu) Szimetikont tartalmazó orális, szilárd adagolási forma
HK1095518A1 (en) Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
CA2199778A1 (en) Extended release formulation of venlafaxine
GEP20053614B (en) Compositions for Oral Administration Containing Opioid Agonist
HUP0203556A2 (hu) Oxkarbazepint tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301972A2 (hu) Fentanilszerű szerkezetű opioidot és ketamint tartalmazó hatóanyag-kombináció és ezt tartalmazó gyógyszerkészítmény
HUP0100043A2 (hu) Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
CA2315261A1 (en) Oral pharmaceutical extended release dosage form
HUP0101411A2 (hu) 2-es típusú angiotenzin II receptor agonistákat tartalmazó gyógyszerkészítmények és ezek alkalmazása
WO2002094774A3 (en) Oxcarbazepine dosage forms
CA2325739A1 (en) Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator
HUP0004966A2 (en) Pharmaceutical composition for oral administration in the form of matrix tablet enabling the prolonged release of trimetazidine
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
HK1067299A1 (en) Pharmaceutical compositions containing terbinafineand use thereof
PL343936A1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
HUP0001780A2 (hu) Stabilizált tibolont tartalmazó készítmények és eljárás előállításukra
HUP0402178A2 (hu) 5 HT1 antagonista hatóanyagot tartalmazó gyógyszerkészítmény
WO2005009407A3 (en) Oral pharmaceutical formulations of olanzapine

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished